Published in Nat Rev Drug Discov on August 01, 2013
Trial of Curcumin in Advanced Pancreatic Cancer | NCT00094445
STAT3 Inhibitor for Solid Tumors | NCT00955812
STAT3 DECOY in Head and Neck Cancer | NCT00696176
Resveratrol in Treating Patients With Colorectal Cancer That Can Be Removed By Surgery | NCT00433576
Phase I and II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL) | NCT01419691
AT9283 in Treating Young Patients With Relapsed or Refractory Acute Leukemia | NCT01431664
Erlotinib and Radiation Therapy in Treating Young Patients With Newly Diagnosed Glioma | NCT00124657
Diindolylmethane in Treating Patients With Breast Cancer | NCT01391689
Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer | NCT00513435
Genetic Basis of Primary Immunodeficiencies | NCT00001788
Dasatinib in Treating Patients With Chronic Lymphocytic Leukemia | NCT01441882
Recombinant Interferon Alfa-2b in Treating Patients With Melanoma | NCT01460875
Emerging cytokine networks in colorectal cancer. Nat Rev Immunol (2015) 1.09
Identification of a natural product-like STAT3 dimerization inhibitor by structure-based virtual screening. Cell Death Dis (2014) 0.97
Prostate cancer stem cells: deciphering the origins and pathways involved in prostate tumorigenesis and aggression. Oncotarget (2015) 0.93
Hydroxamic Acid and Benzoic Acid-Based STAT3 Inhibitors Suppress Human Glioma and Breast Cancer Phenotypes In Vitro and In Vivo. Cancer Res (2015) 0.90
A novel small molecular STAT3 inhibitor, LY5, inhibits cell viability, cell migration, and angiogenesis in medulloblastoma cells. J Biol Chem (2014) 0.89
Sleep Health: Reciprocal Regulation of Sleep and Innate Immunity. Neuropsychopharmacology (2016) 0.88
Targeting JAK1/STAT3 signaling suppresses tumor progression and metastasis in a peritoneal model of human ovarian cancer. Mol Cancer Ther (2014) 0.87
Sleep loss activates cellular inflammation and signal transducer and activator of transcription (STAT) family proteins in humans. Brain Behav Immun (2014) 0.86
Tanshinone I inhibits tumor angiogenesis by reducing Stat3 phosphorylation at Tyr705 and hypoxia-induced HIF-1α accumulation in both endothelial and tumor cells. Oncotarget (2015) 0.85
Targeting IL4/IL4R for the treatment of epithelial cancer metastasis. Clin Exp Metastasis (2015) 0.84
Jak3, STAT3, and STAT5 inhibit expression of miR-22, a novel tumor suppressor microRNA, in cutaneous T-Cell lymphoma. Oncotarget (2015) 0.84
Therapeutic CK2 inhibition attenuates diverse prosurvival signaling cascades and decreases cell viability in human breast cancer cells. Oncotarget (2014) 0.84
STAT3 inhibition suppresses proliferation of retinoblastoma through down-regulation of positive feedback loop of STAT3/miR-17-92 clusters. Oncotarget (2014) 0.83
Involvement of the janus kinase/signal transducer and activator of transcription signaling pathway in multiple sclerosis and the animal model of experimental autoimmune encephalomyelitis. J Interferon Cytokine Res (2014) 0.83
A Resveratrol Analogue Promotes ERKMAPK-Dependent Stat3 Serine and Tyrosine Phosphorylation Alterations and Antitumor Effects In Vitro against Human Tumor Cells. Mol Pharmacol (2015) 0.83
STAT3 Activation in Circulating Monocytes Contributes to Neovascular Age-Related Macular Degeneration. Curr Mol Med (2016) 0.83
PIAS3 expression in squamous cell lung cancer is low and predicts overall survival. Cancer Med (2015) 0.83
Targeting SH2 domains in breast cancer. Future Med Chem (2014) 0.82
Nifuroxazide induces apoptosis and impairs pulmonary metastasis in breast cancer model. Cell Death Dis (2015) 0.82
The oncogenic FIP1L1-PDGFRα fusion protein displays skewed signaling properties compared to its wild-type PDGFRα counterpart. JAKSTAT (2015) 0.81
A chemogenomic screening identifies CK2 as a target for pro-senescence therapy in PTEN-deficient tumours. Nat Commun (2015) 0.81
Targeted inhibition of STATs and IRFs as a potential treatment strategy in cardiovascular disease. Oncotarget (2016) 0.81
Structural basis for DNA recognition by STAT6. Proc Natl Acad Sci U S A (2016) 0.80
Salinomycin Promotes Anoikis and Decreases the CD44+/CD24- Stem-Like Population via Inhibition of STAT3 Activation in MDA-MB-231 Cells. PLoS One (2015) 0.79
Modulation of hepcidin to treat iron deregulation: potential clinical applications. Expert Rev Hematol (2015) 0.79
Identification of STAT1 and STAT3 specific inhibitors using comparative virtual screening and docking validation. PLoS One (2015) 0.79
STAT-dependent upregulation of 12/15-lipoxygenase contributes to neuronal injury after stroke. J Cereb Blood Flow Metab (2015) 0.78
Hirsutinolide Series Inhibit Stat3 Activity, Alter GCN1, MAP1B, Hsp105, G6PD, Vimentin, TrxR1, and Importin α-2 Expression, and Induce Antitumor Effects against Human Glioma. J Med Chem (2015) 0.78
Role of CPS1 in Cell Growth, Metabolism, and Prognosis in LKB1-Inactivated Lung Adenocarcinoma. J Natl Cancer Inst (2017) 0.78
Vascular endothelial growth factor A as predictive marker for mTOR inhibition in relapsing high-grade serous ovarian cancer. BMC Syst Biol (2016) 0.77
Inhibition of Stat3 signaling pathway by nifuroxazide improves antitumor immunity and impairs colorectal carcinoma metastasis. Cell Death Dis (2017) 0.77
The Antiproliferative and Colony-suppressive Activities of STAT3 Inhibitors in Human Cancer Cells Is Compromised Under Hypoxic Conditions. Anticancer Res (2017) 0.77
The impact of the Cancer Genome Atlas on lung cancer. Transl Res (2015) 0.77
Commentary: IL-4 and IL-13 receptors and signaling. Cytokine (2015) 0.77
Novel synthetic (E)-2-methoxy-4-(3-(4-methoxyphenyl) prop-1-en-1-yl) phenol inhibits arthritis by targeting signal transducer and activator of transcription 3. Sci Rep (2016) 0.76
15∝-methoxypuupehenol induces antitumor effects in vitro and in vivo against human glioblastoma and breast cancer models. Mol Cancer Ther (2017) 0.75
Mechanisms and consequences of Jak-STAT signaling in the immune system. Nat Immunol (2017) 0.75
The Potential Therapeutic Application of Peptides and Peptidomimetics in Cardiovascular Disease. Front Pharmacol (2017) 0.75
Evaluation of quantitative assays for the identification of direct signal transducer and activator of transcription 3 (STAT3) inhibitors. Oncotarget (2016) 0.75
Targeting the cyclophilin domain of Ran-binding protein 2 (Ranbp2) with novel small molecules to control the proteostasis of STAT3, hnRNPA2B1 and M-opsin. ACS Chem Neurosci (2015) 0.75
Loss of SOCS3 in myeloid cells prolongs survival in a syngeneic model of glioma. Oncotarget (2016) 0.75
Role of suppressors of cytokine signaling 3 in bone inflammatory responses. Front Immunol (2014) 0.75
Effect of N-Feruloylserotonin and Methotrexate on Severity of Experimental Arthritis and on Messenger RNA Expression of Key Proinflammatory Markers in Liver. J Immunol Res (2016) 0.75
Role of STAT3 in Genesis and Progression of Human Malignant Gliomas. Mol Neurobiol (2016) 0.75
Novel STAT binding elements mediate IL-6 regulation of MMP-1 and MMP-3. Sci Rep (2017) 0.75
Emerging immunotherapies for rheumatoid arthritis. Hum Vaccin Immunother (2014) 0.75
Reduction-oxidation pathways involved in cancer development: a systematic review of literature reviews. Oncotarget (2017) 0.75
GYF-21, an Epoxide 2-(2-Phenethyl)-Chromone Derivative, Suppresses Innate and Adaptive Immunity via Inhibiting STAT1/3 and NF-κB Signaling Pathways. Front Pharmacol (2017) 0.75
Tumor-related interleukins: old validated targets for new anti-cancer drug development. Mol Cancer (2017) 0.75
Benzotriazoles Reactivate Latent HIV-1 through Inactivation of STAT5 SUMOylation. Cell Rep (2017) 0.75
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol (2008) 23.93
STATs and gene regulation. Science (1997) 16.55
The STATs of cancer--new molecular targets come of age. Nat Rev Cancer (2004) 13.07
Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell (1996) 10.49
Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med (2010) 9.77
STAT3 mutations in the hyper-IgE syndrome. N Engl J Med (2007) 8.99
STATs in oncogenesis. Oncogene (2000) 8.60
Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. Proc Natl Acad Sci U S A (1997) 7.08
Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med (2005) 6.58
The role of STATs in transcriptional control and their impact on cellular function. Oncogene (2000) 6.42
Stattic: a small-molecule inhibitor of STAT3 activation and dimerization. Chem Biol (2006) 6.38
Molecular mechanisms regulating Th1 immune responses. Annu Rev Immunol (2001) 6.30
Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene (2002) 6.17
Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med (2003) 5.96
Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res (2002) 5.84
Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc Natl Acad Sci U S A (2007) 4.77
Stat3 activation is responsible for IL-6-dependent T cell proliferation through preventing apoptosis: generation and characterization of T cell-specific Stat3-deficient mice. J Immunol (1998) 4.74
An interleukin-4-induced transcription factor: IL-4 Stat. Science (1994) 4.71
The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell (2009) 4.47
The JAK-STAT pathway at twenty. Immunity (2012) 4.41
Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood (2010) 4.33
Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med (2012) 4.15
Requirement of STAT5b for sexual dimorphism of body growth rates and liver gene expression. Proc Natl Acad Sci U S A (1997) 4.11
STAT proteins: novel molecular targets for cancer drug discovery. Oncogene (2000) 3.75
Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis. J Exp Med (2011) 3.63
A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells. Proc Natl Acad Sci U S A (2005) 3.46
Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation. J Biol Chem (2001) 3.27
Keratinocyte-specific ablation of Stat3 exhibits impaired skin remodeling, but does not affect skin morphogenesis. EMBO J (1999) 3.19
STAT1 mutations in autosomal dominant chronic mucocutaneous candidiasis. N Engl J Med (2011) 3.11
JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med (2013) 3.07
Validating Stat3 in cancer therapy. Nat Med (2005) 2.96
Targeting STAT3 in cancer: how successful are we? Expert Opin Investig Drugs (2009) 2.58
The role of Stat5a and Stat5b in signaling by IL-2 family cytokines. Oncogene (2000) 2.45
Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res (2006) 2.41
First-in-human trial of a STAT3 decoy oligonucleotide in head and neck tumors: implications for cancer therapy. Cancer Discov (2012) 2.31
The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors. Blood (2011) 2.23
STAT proteins as novel targets for cancer drug discovery. Expert Opin Ther Targets (2004) 2.21
Effect of targeted disruption of STAT4 and STAT6 on the induction of experimental autoimmune encephalomyelitis. J Clin Invest (2001) 2.19
Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia. Oncogene (1996) 2.17
Targeting Stat3 in cancer therapy. Anticancer Drugs (2005) 2.13
Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma. J Hepatol (2011) 2.12
Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity. Mol Cancer Ther (2004) 2.10
Gene therapy with dominant-negative Stat3 suppresses growth of the murine melanoma B16 tumor in vivo. Cancer Res (1999) 2.09
Stat5b is essential for natural killer cell-mediated proliferation and cytolytic activity. J Exp Med (1998) 2.07
Synthetic oleanane and ursane triterpenoids with modified rings A and C: a series of highly active inhibitors of nitric oxide production in mouse macrophages. J Med Chem (2000) 2.03
Indirubin derivatives inhibit Stat3 signaling and induce apoptosis in human cancer cells. Proc Natl Acad Sci U S A (2005) 2.00
Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts. Proc Natl Acad Sci U S A (2012) 1.94
Novel STAT3 phosphorylation inhibitors exhibit potent growth-suppressive activity in pancreatic and breast cancer cells. Cancer Res (2010) 1.91
Targeting Stat3 abrogates EGFR inhibitor resistance in cancer. Clin Cancer Res (2012) 1.89
Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs). Oncogene (2004) 1.82
Pyridone 6, a pan-Janus-activated kinase inhibitor, induces growth inhibition of multiple myeloma cells. Cancer Res (2006) 1.80
An oxazole-based small-molecule Stat3 inhibitor modulates Stat3 stability and processing and induces antitumor cell effects. ACS Chem Biol (2007) 1.79
Niflumic acid suppresses interleukin-13-induced asthma phenotypes. Am J Respir Crit Care Med (2006) 1.79
Functional roles of STAT family proteins: lessons from knockout mice. Stem Cells (1999) 1.72
Interleukin-4, interleukin-13, signal transducer and activator of transcription factor 6, and allergic asthma. Curr Mol Med (2008) 1.64
Investigation of the binding determinants of phosphopeptides targeted to the SRC homology 2 domain of the signal transducer and activator of transcription 3. Development of a high-affinity peptide inhibitor. J Med Chem (2005) 1.62
Ursolic acid inhibits STAT3 activation pathway leading to suppression of proliferation and chemosensitization of human multiple myeloma cells. Mol Cancer Res (2007) 1.61
Stat5a is tyrosine phosphorylated and nuclear localized in a high proportion of human breast cancers. Int J Cancer (2004) 1.60
Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance. Clin Cancer Res (2013) 1.59
A novel small-molecule disrupts Stat3 SH2 domain-phosphotyrosine interactions and Stat3-dependent tumor processes. Biochem Pharmacol (2010) 1.56
Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3. Blood (2008) 1.53
Resveratrol addiction: to die or not to die. Mol Nutr Food Res (2009) 1.50
Th1 versus Th17: are T cell cytokines relevant in multiple sclerosis? Biochim Biophys Acta (2010) 1.50
IL-4 regulates skin homeostasis and the predisposition toward allergic skin inflammation. J Immunol (2010) 1.49
Cryptotanshinone inhibits constitutive signal transducer and activator of transcription 3 function through blocking the dimerization in DU145 prostate cancer cells. Cancer Res (2009) 1.47
Identification of a high-affinity phosphopeptide inhibitor of Stat3. Bioorg Med Chem Lett (2003) 1.46
Inhibition of growth and metastasis of human hepatocellular carcinoma by antisense oligonucleotide targeting signal transducer and activator of transcription 3. Clin Cancer Res (2006) 1.46
The IL-4/IL-13/Stat6 signalling pathway promotes luminal mammary epithelial cell development. Development (2007) 1.46
Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells. Mol Cancer Ther (2007) 1.45
Cucurbitacin E, a tetracyclic triterpenes compound from Chinese medicine, inhibits tumor angiogenesis through VEGFR2-mediated Jak2-STAT3 signaling pathway. Carcinogenesis (2010) 1.44
BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance. J Hematol Oncol (2011) 1.43
Chemosensitization of tumors by resveratrol. Ann N Y Acad Sci (2011) 1.41
Targeting signal transducer and activator of transcription signaling pathway in leukemias. J Clin Oncol (2009) 1.40
Antiproliferative mechanisms of a transcription factor decoy targeting signal transducer and activator of transcription (STAT) 3: the role of STAT1. Mol Pharmacol (2007) 1.39
Chemical probes that competitively and selectively inhibit Stat3 activation. PLoS One (2009) 1.37
Discovery of chromone-based inhibitors of the transcription factor STAT5. Chembiochem (2008) 1.34
Potent and selective phosphopeptide mimetic prodrugs targeted to the Src homology 2 (SH2) domain of signal transducer and activator of transcription 3. J Med Chem (2011) 1.34
STAT3 is activated by JAK2 independent of key oncogenic driver mutations in non-small cell lung carcinoma. PLoS One (2012) 1.33
Biological activity of piceatannol: leaving the shadow of resveratrol. Mutat Res (2012) 1.33
Sorafenib induces growth arrest and apoptosis of human glioblastoma cells through the dephosphorylation of signal transducers and activators of transcription 3. Mol Cancer Ther (2010) 1.33
JAK1 activates STAT3 activity in non-small-cell lung cancer cells and IL-6 neutralizing antibodies can suppress JAK1-STAT3 signaling. Mol Cancer Ther (2011) 1.29
Curcumin blocks small cell lung cancer cells migration, invasion, angiogenesis, cell cycle and neoplasia through Janus kinase-STAT3 signalling pathway. PLoS One (2012) 1.27
A chemical biology approach to developing STAT inhibitors: molecular strategies for accelerating clinical translation. Oncotarget (2011) 1.26
Honokiol inhibits epidermal growth factor receptor signaling and enhances the antitumor effects of epidermal growth factor receptor inhibitors. Clin Cancer Res (2010) 1.25
Antiangiogenic and antimetastatic activity of JAK inhibitor AZD1480. Cancer Res (2011) 1.23
Retracted γ-Tocotrienol but not γ-tocopherol blocks STAT3 cell signaling pathway through induction of protein-tyrosine phosphatase SHP-1 and sensitizes tumor cells to chemotherapeutic agents. J Biol Chem (2010) 1.23
CDDO-Me, a synthetic triterpenoid, inhibits expression of IL-6 and Stat3 phosphorylation in multi-drug resistant ovarian cancer cells. Cancer Chemother Pharmacol (2008) 1.23
Therapeutic potential of AZD1480 for the treatment of human glioblastoma. Mol Cancer Ther (2011) 1.22
Curcumin induces the differentiation of myeloid-derived suppressor cells and inhibits their interaction with cancer cells and related tumor growth. Cancer Prev Res (Phila) (2011) 1.21
Withaferin A inhibits activation of signal transducer and activator of transcription 3 in human breast cancer cells. Carcinogenesis (2010) 1.19
Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin. Int J Oncol (2008) 1.19
Structure-Based Design of Conformationally Constrained, Cell-Permeable STAT3 Inhibitors. ACS Med Chem Lett (2010) 1.18
Interleukin-13 augments bronchial smooth muscle contractility with an up-regulation of RhoA protein. Am J Respir Cell Mol Biol (2008) 1.17
Lack of toxicity of a STAT3 decoy oligonucleotide. Cancer Chemother Pharmacol (2008) 1.16
Celastrol suppresses growth and induces apoptosis of human hepatocellular carcinoma through the modulation of STAT3/JAK2 signaling cascade in vitro and in vivo. Cancer Prev Res (Phila) (2012) 1.16
Isoform selective inhibition of STAT1 or STAT3 homo-dimerization via peptidomimetic probes: structural recognition of STAT SH2 domains. Bioorg Med Chem Lett (2007) 1.15
Emodin has a cytotoxic activity against human multiple myeloma as a Janus-activated kinase 2 inhibitor. Mol Cancer Ther (2007) 1.15
Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene (2002) 6.17
Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc Natl Acad Sci U S A (2007) 4.77
Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene (2005) 3.05
Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin Cancer Res (2006) 3.00
Mechanisms of disease: Insights into the emerging role of signal transducers and activators of transcription in cancer. Nat Clin Pract Oncol (2005) 2.96
Targeting STAT3 in cancer: how successful are we? Expert Opin Investig Drugs (2009) 2.58
Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells. Oncogene (2003) 2.54
STAT3 as a target for inducing apoptosis in solid and hematological tumors. Cell Res (2008) 2.46
Stat3 controls lysosomal-mediated cell death in vivo. Nat Cell Biol (2011) 2.28
Indirubin derivatives inhibit Stat3 signaling and induce apoptosis in human cancer cells. Proc Natl Acad Sci U S A (2005) 2.00
Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts. Proc Natl Acad Sci U S A (2012) 1.94
An oxazole-based small-molecule Stat3 inhibitor modulates Stat3 stability and processing and induces antitumor cell effects. ACS Chem Biol (2007) 1.79
A STAT3-mediated metabolic switch is involved in tumour transformation and STAT3 addiction. Aging (Albany NY) (2010) 1.70
Resveratrol inhibits Src and Stat3 signaling and induces the apoptosis of malignant cells containing activated Stat3 protein. Mol Cancer Ther (2006) 1.69
Constitutively active Stat3 enhances neu-mediated migration and metastasis in mammary tumors via upregulation of Cten. Cancer Res (2010) 1.60
A novel small-molecule disrupts Stat3 SH2 domain-phosphotyrosine interactions and Stat3-dependent tumor processes. Biochem Pharmacol (2010) 1.56
Cytoplasmic transport of Stat3 by receptor-mediated endocytosis. EMBO J (2002) 1.43
The high-mobility group A1a/signal transducer and activator of transcription-3 axis: an achilles heel for hematopoietic malignancies? Cancer Res (2008) 1.43
Hepatitis C virus (HCV) constitutively activates STAT-3 via oxidative stress: role of STAT-3 in HCV replication. J Virol (2005) 1.39
The impact of ovulation on fallopian tube epithelial cells: evaluating three hypotheses connecting ovulation and serous ovarian cancer. Endocr Relat Cancer (2011) 1.39
Molecular approaches towards the inhibition of the signal transducer and activator of transcription 3 (Stat3) protein. ChemMedChem (2008) 1.38
A functional nuclear epidermal growth factor receptor, SRC and Stat3 heteromeric complex in pancreatic cancer cells. PLoS One (2011) 1.29
Targeting protein-protein interactions: suppression of Stat3 dimerization with rationally designed small-molecule, nonpeptidic SH2 domain binders. Chembiochem (2008) 1.21
Disruption of transcriptionally active Stat3 dimers with non-phosphorylated, salicylic acid-based small molecules: potent in vitro and tumor cell activities. Chembiochem (2009) 1.20
Cell-to-cell adhesion modulates Stat3 activity in normal and breast carcinoma cells. Oncogene (2004) 1.19
Isoform selective inhibition of STAT1 or STAT3 homo-dimerization via peptidomimetic probes: structural recognition of STAT SH2 domains. Bioorg Med Chem Lett (2007) 1.15
The R(h)oads to Stat3: Stat3 activation by the Rho GTPases. Exp Cell Res (2011) 1.12
Enhanced sensitivity of pancreatic cancer cells to concurrent inhibition of aberrant signal transducer and activator of transcription 3 and epidermal growth factor receptor or Src. J Pharmacol Exp Ther (2010) 1.12
A cell-permeable Stat3 SH2 domain mimetic inhibits Stat3 activation and induces antitumor cell effects in vitro. J Biol Chem (2010) 1.09
Small molecule STAT5-SH2 domain inhibitors exhibit potent antileukemia activity. J Med Chem (2012) 1.03
Sensitization of pancreatic cancer cells to radiation by cerium oxide nanoparticle-induced ROS production. Nanomedicine (2012) 1.01
Identification of a non-phosphorylated, cell permeable, small molecule ligand for the Stat3 SH2 domain. Bioorg Med Chem Lett (2011) 1.00
Stat3 is required for full neoplastic transformation by the Simian Virus 40 large tumor antigen. Mol Biol Cell (2005) 0.99
Antagonism of the Stat3-Stat3 protein dimer with salicylic acid based small molecules. ChemMedChem (2011) 0.99
The RhoU/Wrch1 Rho GTPase gene is a common transcriptional target of both the gp130/STAT3 and Wnt-1 pathways. Biochem J (2009) 0.94
Ligand-independent phosphorylation of Y869 (Y845) links mutant EGFR signaling to stat-mediated gene expression. Exp Cell Res (2007) 0.93
Alginate hydrogels for three-dimensional organ culture of ovaries and oviducts. J Vis Exp (2011) 0.92
Three-dimensional ovarian organ culture as a tool to study normal ovarian surface epithelial wound repair. Endocrinology (2009) 0.91
Design, synthesis, and in vitro characterization of novel hybrid peptidomimetic inhibitors of STAT3 protein. Bioorg Med Chem (2010) 0.90
Coordination complex SH2 domain proteomimetics: an alternative approach to disrupting oncogenic protein-protein interactions. Chem Commun (Camb) (2009) 0.85
Identification of Purine-Scaffold Small-Molecule Inhibitors of Stat3 Activation by QSAR Studies. ACS Med Chem Lett (2010) 0.85
A New Metabolite with a Unique 4-Pyranone-γ-Lactam-1,4-Thiazine Moiety from a Hawaiian-Plant Associated Fungus. Org Lett (2015) 0.83
An activatable multimodal/multifunctional nanoprobe for direct imaging of intracellular drug delivery. Biomaterials (2011) 0.83
Differential effects of Stat3 inhibition in sparse vs confluent normal and breast cancer cells. Cancer Lett (2005) 0.81
THAP5 is a DNA-binding transcriptional repressor that is regulated in melanoma cells during DNA damage-induced cell death. Biochem Biophys Res Commun (2010) 0.81
Artificially induced protein-membrane anchorage with cholesterol-based recognition agents as a new therapeutic concept. Angew Chem Int Ed Engl (2011) 0.79
Hirsutinolide Series Inhibit Stat3 Activity, Alter GCN1, MAP1B, Hsp105, G6PD, Vimentin, TrxR1, and Importin α-2 Expression, and Induce Antitumor Effects against Human Glioma. J Med Chem (2015) 0.78
Buffer-stable chitosan-polyglutamic acid hybrid nanoparticles for biomedical applications. Macromol Biosci (2013) 0.77
In situ electroporation of large numbers of cells using minimal volumes of material. Anal Biochem (2003) 0.77
Nanoparticle delivery of inhibitory signal transducer and activator of transcription 3 G-quartet oligonucleotides blocks tumor growth in HMGA1 transgenic model of T-cell leukemia. Leuk Lymphoma (2013) 0.77